Coherus BioSciences Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
CHRS$0.82+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, | |||||||||
| · · 2023 · 2022 · 2021 | |||||||||
| Net revenue | | $257,244 | | $211,042 | | $326,551 | |||
| Costs and expenses: | | | | | | | |||
| Cost of goods sold | | 158,992 | | 70,083 | | 57,591 | |||
| Research and development | | 109,436 | | 199,358 | | 363,105 | |||
| Selling, general and administrative | | 192,015 | | 198,481 | | 169,713 | |||
| Total costs and expenses | | 460,443 | | 467,922 | | 590,409 | |||
| Loss from operations | | (203,199) | | (256,880) | | (263,858) | |||
| Interest expense | | (40,542) | | (32,474) | | (22,959) | |||
| Loss on debt extinguishment | | | — | | | (6,222) | | | — |
| Other income (expense), net | | 5,469 | | 3,822 | | (283) | |||
| Loss before income taxes | | (238,272) | | (291,754) | | (287,100) | |||
| Income tax provision (benefit) | | (380) | | — | | — | |||
| Net loss | | $(237,892) | | $(291,754) | | $(287,100) | |||
| | | | | ||||||
| Basic and diluted net loss per share | | $(2.53) | | $(3.76) | | $(3.81) | |||
| | | | | | | | | | |
| Weighted-average number of shares used in computing basic and diluted net loss per share | | 94,162,637 | | 77,630,020 | | 75,449,632 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.